先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02096 先声药业

未开盘 11-06 16:08:52

11.090

-0.080

-0.72%

最高11.320	最低10.870	成交量443.31万
今开11.000	昨收11.170	日振幅4.03%
总市值284.79亿	流通市值284.79亿	总股本25.68亿
成交额4,945万	换手率0.17%	流通股本25.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":11.09,"timestamp":1793952532005,"preClose":11.17,"halted":0,"volume":4433060,"delay":0,"changeRate":-0.007162041181736801,"floatShares":2568000000,"shares":2568000000,"eps":0.54,"marketStatus":"未开盘","change":-0.08,"latestTime":"11-06 16:08:52","open":11,"high":11.32,"low":10.87,"amount":49450336,"amplitude":0.040286,"askPrice":11.13,"askSize":4000,"bidPrice":11.09,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.703662,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":0,"adr":0,"listingDate":1603728000000,"exchange":"SEHK","adjPreClose":11.17,"dividendRate":0.018638,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.6173827792197369,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096/wiki","defaultTab":"wiki","newsList":[{"id":"2681783687","title":"先声药业（02096）：泽普昔替尼治疗类风湿关节炎新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2681783687","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681783687?lang=zh_cn&edition=full","pubTime":"2026-11-06 12:27","pubTimestamp":1793939263,"startTime":"0","endTime":"0","summary":"金吾财讯 | 先声药业（02096）发布公告，集团与凌科药业（浙江）股份有限公司合作的高选择性第二代JAK1抑制剂泽普昔替尼用于治疗中重度活动性类风湿关节炎的新药上市申请，已获中国国家药品监督管理局正式受理。这是泽普昔替尼在中国继成人中重度特应性皮炎适应症后，进入注册审评阶段的第二个适应症。公告披露，研究结果显示，在主要终点及关键次要终点上，泽普昔替尼较安慰剂组均展现出具有统计学意义（p＜0.0001）的疗效优势，且整体安全性和耐受性良好。此外，在疾病活动度评分（DAS28-CRP≤3.2）和身体功能改善（HAQ-DI改善≥0.22）等指标方面，泽普昔替尼同样展现出持续且稳定的疗效。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/YThlNWYyZDkwZDI4NjgyMzY1OTg4MDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YThlNWYyZDkwZDI4NjgyMzY1OTg4MDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995424","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02096","BK1191","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148060918","title":"先声药业（02096）与凌科药业合作开发的泽普昔替尼类风湿关节炎新药申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1148060918","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148060918?lang=zh_cn&edition=full","pubTime":"2026-11-06 12:12","pubTimestamp":1793938376,"startTime":"0","endTime":"0","summary":"2026年11月6日，先声药业集团有限公司发布自愿公告称，其与凌科药业（浙江）股份有限公司合作研发的高选择性第二代 JAK1 抑制剂泽普昔替尼，用于治疗中重度活动性类风湿关节炎的新药上市申请已获中国国家药品监督管理局正式受理。这是继成人中重度特应性皮炎适应症后，泽普昔替尼在中国进入注册审评阶段的第二个适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115213236","title":"先声药业10月股份变动月报表披露，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1115213236","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115213236?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:32","pubTimestamp":1793784761,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年11月4日披露了截至2026年10月31日的证券变动月报表。公告显示，公司10月底已发行普通股总数与月初持平，均为2,568,198,618股，未有新增发行或注销，库存股份数为0。根据公告，先声药业并无法定股本概念，因此本月未发生法定或注册股本的变动。先声药业方面表示，将继续遵守香港联交所相关规则及法规，确保公司股本信息的合规与透明。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680700501","title":"港股异动 | 先声药业(02096)涨超2% 与凌科药业就选择性JAK1抑制剂泽普昔替尼进一步达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2680700501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680700501?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:41","pubTimestamp":1793760103,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业涨超2%，截至发稿，涨1.96%，报10.39港元，成交额2521.72万港元。消息面上，先声药业发布公告，于2026年11月2日，本集团与凌科药业(浙江)股份有限公司就选择性JAK1抑制剂泽普昔替尼进一步达成合作。本集团与凌科药业于2022年3月达成合作，获得泽普昔替尼在中国大陆及港澳台地区针对类风湿关节炎及强直性脊柱炎的独家商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK1191","VXUS","BK4588","BK1583","02096","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680685700","title":"港股异动 | 先声药业(02096.HK)涨超2% 与凌科药业就选择性JAK1抑制剂泽普昔替尼进一步达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2680685700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680685700?lang=zh_cn&edition=full","pubTime":"2026-11-04 10:41","pubTimestamp":1793760103,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106831811","title":"先声药业集团有限公司11月3日回购52.8万股，耗资约536.34万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106831811","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106831811?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:06","pubTimestamp":1793703961,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年11月3日发布公告，披露于香港联交所场内回购普通股528,000股，占公司已发行股本约0.02%。此次回购的每股价格介于10.10港元至10.19港元之间，合计付出价格约536.34万港元。根据公告，回购后公司已发行股本数目维持2,568,198,618股，库藏股数为0股。先声药业集团有限公司的购回授权由股东于2026年6月12日通过，可供回购的股份总数为256,819,861股。公告由先声药业集团有限公司联席公司秘书朱达签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业集团有限公司11月3日回购52.8万股，耗资约536.34万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680747678","title":"先声药业(02096.HK)11月3日斥资536.34万港元回购52.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680747678","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680747678?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:04","pubTimestamp":1793703884,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680054759","title":"彭素琴增持先声药业(02096)20万股 每股作价10.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680054759","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680054759?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:46","pubTimestamp":1793619971,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月28日，彭素琴增持先声药业(02096)20万股，每股作价10.28港元，总金额为205.6万港元。增持后最新持股数目约为17.31亿股，最新持股比例为67.40%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169954945","title":"先声药业(02096)扩展泽普昔替尼商业化布局　取得中重度特应性皮炎等皮科适应症独家推广权","url":"https://stock-news.laohu8.com/highlight/detail?id=1169954945","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169954945?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:03","pubTimestamp":1793610203,"startTime":"0","endTime":"0","summary":"2026年11月2日，先声药业集团有限公司发布自愿公告称，与凌科药业（浙江）股份有限公司就选择性JAK1抑制剂泽普昔替尼签订独家推广服务协议。根据协议，先声药业将获得泽普昔替尼在中国大陆及港澳台地区用于成人中重度特应性皮炎及其他皮科适应症的独家商业化权益。公告回顾，双方曾于2022年3月达成合作，先声药业已取得泽普昔替尼在中国大陆及港澳台地区治疗类风湿关节炎及强直性脊柱炎的独家商业化权益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680732969","title":"先声药业(02096)与凌科药业就泽普昔替尼皮科适应症订立独家推广服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2680732969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680732969?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:58","pubTimestamp":1793609910,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业 发布公告，于2026年11月2日，本集团与凌科药业(浙江)股份有限公司就选择性JAK1抑制剂泽普昔替尼进一步达成合作。本集团与凌科药业于2022年3月达成合作，获得泽普昔替尼在中国大陆及港澳台地区针对类风湿关节炎及强直性脊柱炎的独家商业化权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","KCE","01276","HK0000320264.USD","BK0028","01093","LU0455707207.USD","LU0588546209.SGD","01952","LU1969619763.USD","LU0348825331.USD","01951","09939","02162","02268","LU0823426480.USD","LU0708995153.HKD","02273","06078","00013","LU0607220059.USD","KURE","LU0708995583.HKD","01530","02269","06821","01548","LU0348766576.USD","09996","LU0039217434.USD","01177","159938","09966","IE00B031HY20.USD","06030","06996","600030","LU0828237510.HKD","LU1064131003.USD","03759","03692","02596","09926","LU1226287529.USD","06990","01801","06160","LU1794554557.SGD","02096","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133177829","title":"先声药业10月27日回购104.20万股，涉资约1,075.10万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133177829","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133177829?lang=zh_cn&edition=full","pubTime":"2026-10-27 17:42","pubTimestamp":1793094122,"startTime":"0","endTime":"0","summary":"先声药业于2026年10月27日发布公告，披露当日于香港联交所回购公司股份。此次回购股份数量为104.20万股，约占公司已发行股本的0.04%，每股回购价介乎港币10.15元至10.41元，合计耗资约1,075.10万港元。根据2026年6月12日通过的回购授权，先声药业可回购的股份总数为256,819,861股，迄今已累计回购11,829,000股，占授权总额的4.61%。公司同时确认，本次股份回购已取得董事会正式授权，并遵守了香港联交所证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业10月27日回购104.20万股，涉资约1,075.10万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164816328","title":"先声药业回购110.20万股股份，总额约1,167.05万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164816328","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164816328?lang=zh_cn&edition=full","pubTime":"2026-10-26 18:07","pubTimestamp":1793009259,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年10月26日发布公告，当日通过香港联合交易所场内回购普通股约110.20万股，占已发行股本约0.043%。本次回购价格每股介乎港币10.49元至港币10.64元，总涉资约港币1,167.05万元。由于回购股份尚未注销，公司已发行股本仍为2,568,198,618股，且库藏股数为0。公司可依据该授权回购股份的总数为256,819,861股，截至目前已累计在香港联交所或其他证券交易所回购10,787,000股，占授权通过当日已发行股份总数的4.2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业回购110.20万股股份，总额约1,167.05万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678866161","title":"先声药业(02096)10月26日斥资1167.05万港元回购110.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678866161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678866161?lang=zh_cn&edition=full","pubTime":"2026-10-26 18:01","pubTimestamp":1793008892,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年10月26日，该公司斥资1167.05万港元回购110.2万股股份，每股回购价10.49-10.64港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155185817","title":"先声药业集团回购33.90万股股份，总额约363.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155185817","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155185817?lang=zh_cn&edition=full","pubTime":"2026-10-23 18:46","pubTimestamp":1792752377,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司2026年10月23日发布公告，宣布于当日回购339,000股普通股，占该次回购前公司已发行股本约0.013%。每股回购价介乎每股10.63港元至10.76港元，涉及总金额约363.24万港元。根据公告显示，回购股份尚未注销，截至2026年10月23日，公司已发行股本仍约为2,568,198,618股，库藏股数为0。公司确认本次回购行为符合香港联交所证券上市规则及相关法律法规。公告由先声药业集团有限公司联席公司秘书朱达签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业集团回购33.90万股股份，总额约363.24万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677448925","title":"先声药业(02096)10月23日耗资约363.24万港元回购33.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677448925","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677448925?lang=zh_cn&edition=full","pubTime":"2026-10-23 18:44","pubTimestamp":1792752272,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)公布，2026年10月23日耗资约363.24万港元回购33.9万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198195545","title":"先声药业回购147.70万股，耗资约1543.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198195545","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198195545?lang=zh_cn&edition=full","pubTime":"2026-10-22 17:46","pubTimestamp":1792662382,"startTime":"0","endTime":"0","summary":"先声药业于2026年10月22日发布公告，披露当日于香港联交所场内回购股份147.70万股，约占公司已发行股本的0.058%。本次回购每股价格介于10.36港元至10.6414港元之间，合计支付金额约1543.46万港元。公告显示，本次交易完成后，先声药业的已发行股本仍为2,568,198,618股，且无任何库藏股。先声药业同时确认，本次股份回购符合香港联交所证券上市规则及相关适用法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业回购147.70万股，耗资约1543.46万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677058955","title":"先声药业(02096)10月22日斥资1543.46万港元回购147.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677058955","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677058955?lang=zh_cn&edition=full","pubTime":"2026-10-22 17:43","pubTimestamp":1792662229,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，该公司于2026年10月22日斥资1543.46万港元回购147.7万股股份，每股回购价格为10.36-10.6414港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677958931","title":"瑞银：降联邦制药(03933.HK)评级至“中性” 重申先声药业(02096.HK)为首选","url":"https://stock-news.laohu8.com/highlight/detail?id=2677958931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677958931?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:41","pubTimestamp":1792658506,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02096","IE00B3M56506.USD","BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675593659","title":"先声药业任晋生，被时代冷落的大佬","url":"https://stock-news.laohu8.com/highlight/detail?id=2675593659","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675593659?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:52","pubTimestamp":1792144329,"startTime":"0","endTime":"0","summary":"被时代冷落，有时不是因为不努力。1995年，江苏先声药业正式成立。但任晋生的眼光，没有停在\"卖药赚钱\"上。那年4月20日，先声药业登陆纽交所，募资2.61亿美元，成为第一家登陆纽交所的中国化学生物制药企业。任晋生，是那个孤独的先行者。任晋生选的，是多点开花、分散风险的开放生态。任命一公布，就掀起了合规争议。2026年8月，任晋生重新兼任CEO。先声的尴尬在于，它总比时代快半","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792120311600840862","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":0.0937},{"period":"1month","weight":-0.0272},{"period":"3month","weight":-0.1092},{"period":"6month","weight":-0.053},{"period":"1year","weight":-0.1227},{"period":"ytd","weight":-0.0538}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家主要从事研发、制造及销售药品的投资控股公司。该公司主要通过两个分部运营其业务。抗肿瘤领域业务分部主要从事抗肿瘤药品的研发、生产、销售及商业化。其他药品业务分部主要从事聚焦于数个治疗领域包括神经科学领域、自身免疫领域及抗感染领域药品的研发、生产、销售及商业化。该公司还从事提供药品的商业化服务。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.09318},{"month":2,"riseRate":0.666667,"avgChangeRate":0.070754},{"month":3,"riseRate":0.5,"avgChangeRate":-0.014037},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.105952},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032044},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.001102},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.059624},{"month":9,"riseRate":0.5,"avgChangeRate":-0.015742},{"month":10,"riseRate":0.666667,"avgChangeRate":0.066568},{"month":11,"riseRate":0.714286,"avgChangeRate":0.051352},{"month":12,"riseRate":0.5,"avgChangeRate":0.000556}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}